CPT-11 and L-OHP combination versus alternated combination of LV5FU2+CPT-11/LV5FU2+L-OHP in 5-FU resistant advanced colorectal cancer (CRC): Preliminary results

被引：1
|
作者：
Becouam, Y
Mousseau, M
Gamelin, E
Coudert, B
Marceau-Suissa, J
Bekradda, M
机构：
[1] Inst Bergonie Bordeaux, Bordeaux, France
[2] CHU Grenoble, F-38043 Grenoble, France
[3] Ctr Paul Papin, Angers, France
[4] Ctr F Leclerc, Dijon, France
[5] Rhone Poulenc Rorer, Montrouge, France
[6] C&AC Kremlin Bicetre, Le Kremlin Bicetre, France
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)80652-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219
引用
收藏
页码：S71 / S71
页数：1
相关论文
共 50 条
  • [41] A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma
    Gennatas, C.
    Papaxoinis, G.
    Michalaki, V.
    Mouratidou, D.
    Andreadis, Ch.
    Tsavaris, N.
    Pafiti, A.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (05) : 538 - 544
  • [42] Combination of Capecitabine (Xeloda), Oxaliplatin (L-OHP), and Irinotecan (CPT-11) (COI regimen) in patients with advanced gastrointestinal tumor
    Bajetta, Emilio
    Di Bartolomeo, Maria
    Ferrario, Erminia
    Beretta, Elena
    Bianchini, Giampaolo
    De Dosso, Sara
    Buzzoni, Roberto
    ANNALS OF ONCOLOGY, 2004, 15 : 82 - 82
  • [43] Appropriate schedule of oral tegafur / uracil (UFT) in combination with irinotecan (CPT-11) and bolus 5-FU / l-leucovorin (LV) in patients (pts) with metastatic colorectal cancer (MCRC): A phase I study
    Chayahara, N.
    Tamura, T.
    Miki, I.
    Okuno, T.
    Kamigaki, T.
    Nishisaki, H.
    Inoue, Y.
    Maeda, T.
    Sakaeda, T.
    Azuma, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Oxaliplatin (L-OHP) in combination with 5-fluorouracil (5-FU)/l-leucovorin (l-LV) on modified Roswell Park regimen as first-line treatment of advanced colorectal cancer (ACRC):: A phase I/II study.
    Miyata, Y
    Shirao, K
    Ohtsu, A
    Boku, N
    Tanigawara, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 295S - 295S
  • [45] The experience of the TTD Spanish Cooperative Group in advanced colorectal cancer resistant to 5-FU with irinotecan (CPT-11) on a 3 weeks schedule: Final results
    Anton, A
    Aranda, E
    Marcuello, E
    Massuti, B
    Carrato, A
    Abad, A
    Cervantes, A
    Fernandez-Martos, C
    Sastre, J
    Gallen, M
    ANNALS OF ONCOLOGY, 1998, 9 : 39 - 39
  • [46] The Combination of 5-FU, Leucovorin and CPT-11 (FOLFIRI) Prolongs Survival through Inhibition of Metastasis in an Orthotopic Model of Colon Cancer
    Ishihara, Yoko
    Matsunaga, Kenichi
    Iijima, Hiroko
    Hasegawa, Go
    Suzuki, Toshimitsu
    Sato, Atsushi
    Kobayashi, Tomowo
    Yang, Meng
    Hoffman, Robert M.
    ANTICANCER RESEARCH, 2010, 30 (02) : 403 - 408
  • [47] Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan
    Tai, CJ
    Liu, JH
    Chen, WS
    Lin, JK
    Wang, WS
    Yen, CC
    Chiou, TJ
    Chen, PM
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (03) : 136 - 140
  • [48] Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer
    M. Benavides
    P. García-Alfonso
    M. Cobo
    A. Muñoz-Martín
    S. Gil-Calle
    F. Carabantes
    E. Villar
    J. Graupera
    M. Balcells
    G. Pérez-Manga
    Medical Oncology, 2004, 21 : 255 - 262
  • [49] Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer
    Benavides, M
    García-Alfonso, P
    Cobo, M
    Cobo, T
    Muñoz-Martín, A
    Gil-Calle, S
    Carabantes, F
    Villar, E
    Graupera, J
    Balcells, M
    Pérez-Manga, G
    MEDICAL ONCOLOGY, 2004, 21 (03) : 255 - 262
  • [50] CPT-11 combined or alternated with 5 fluoruracil folinic acid (5-FU/FA) vs Mayo clinic regimen in first line therapy of advanced colorectal cancer (ACRC)
    Graeven, U
    Ridwelski, K
    Manns, M
    Schoelmerich, J
    Espana, P
    Murias, A
    Carlsson, G
    Borner, M
    Oulid-Aissa, D
    Boussard, B
    Schmiegel, W
    GASTROENTEROLOGY, 2001, 120 (05) : A611 - A611
12345